A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu‐Negative Metastatic Breast Cancer and a Single‐Arm, Historically‐Controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I‐III Triple Negative Breast Cancer with High‐Risk Residual Disease (EMPOWER). The gene discussed is ERBB2; the disease is breast cancer.